Study protocol: Optimising patient positioning for the planning of accelerated partial breast radiotherapy for the integrated magnetic resonance linear accelerator: OPRAH MRL.

Autor: Dean J; Radiation Oncology, Olivia Newton John Cancer Wellness and Research Centre, Austin Health, PO Box 5555, Heidelberg, VIC, 3084, Australia. jenna.dean@austin.org.au.; Department of Medical Imaging and Radiation Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Wellington Rd, Clayton, VIC, 3800, Australia. jenna.dean@austin.org.au., Anderson N; Radiation Oncology, Olivia Newton John Cancer Wellness and Research Centre, Austin Health, PO Box 5555, Heidelberg, VIC, 3084, Australia., Halkett GKB; Curtin School of Nursing/Curtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, GPO Box U1987, Perth, WA, 6845, Australia., Lye J; Radiation Oncology, Olivia Newton John Cancer Wellness and Research Centre, Austin Health, PO Box 5555, Heidelberg, VIC, 3084, Australia.; School of Health and Biomedical Science, RMIT University, 124 La Trobe St, Melbourne, VIC, 3000, Australia., Tacey M; Radiation Oncology, Olivia Newton John Cancer Wellness and Research Centre, Austin Health, PO Box 5555, Heidelberg, VIC, 3084, Australia., Foroudi F; Radiation Oncology, Olivia Newton John Cancer Wellness and Research Centre, Austin Health, PO Box 5555, Heidelberg, VIC, 3084, Australia., Chao M; Radiation Oncology, Olivia Newton John Cancer Wellness and Research Centre, Austin Health, PO Box 5555, Heidelberg, VIC, 3084, Australia., Wright C; Department of Medical Imaging and Radiation Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Wellington Rd, Clayton, VIC, 3800, Australia.
Jazyk: angličtina
Zdroj: Radiation oncology (London, England) [Radiat Oncol] 2024 Sep 17; Vol. 19 (1), pp. 123. Date of Electronic Publication: 2024 Sep 17.
DOI: 10.1186/s13014-024-02517-3
Abstrakt: Background: Accelerated partial breast irradiation (APBI) is an accepted treatment option for early breast cancer. Treatment delivered on the Magnetic Resonance integrated Linear Accelerator (MRL) provides the added assurance of improved soft tissue visibility, important in the delivery of APBI. This technique can be delivered in both the supine and prone positions, however current literature suggests that prone treatment on the MRL is infeasible due to physical limitations with bore size. This study aims to investigate the feasibility of positioning patients on a custom designed prone breast board compared with supine positioning on a personalised vacuum bag. Geometric distortion, the relative position of Organs at Risk (OAR) to the tumour bed and breathing motion (intrafraction motion) will be compared between the supine and prone positions. The study will also investigate the positional impact on dosimetry, patient experience, and position preference.
Methods: Up to 30 patients will be recruited over a 12-month period for participation in this Human Research Ethics Committee approved exploratory cohort study. Patients will be scanned on the magnetic resonance imaging (MRI) Simulator in both the supine and prone positions as per current standard of care for APBI simulation. Supine and prone positioning comparisons will all be assessed on de-identified MRI image pairs, acquired using appropriate software. Patient experience will be explored through completion of a short, anonymous electronic survey. Descriptive statistics will be used for reporting of results with categorical, parametric/non-parametric tests applied (data format dependent). Survey results will be interpreted by comparison of percentage frequencies across the Likert scales. Thematic content analysis will be used to interpret qualitative data from the open-ended survey questions.
Discussion: The results of this study will be used to assess the feasibility of treating patients with APBI in the prone position on a custom designed board on the MRL. It may also be used to assist with identification of patients who would benefit from this position over supine without the need to perform both scans. Patient experience and technical considerations will be utilised to develop a tool to assist in this process. Trial registration Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN1262400067583. Registered 28th of May 2024. https://www.anzctr.org.au/ACTRN12624000679583.aspx.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje